China Isotope & Radiation Corporation (1763) H1 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was RMB2,857.8 million, up 1.7% year-over-year, with net profit rising 11.2% to RMB341.0 million and net profit attributable to shareholders up 11.3% to RMB172.0 million.

• Gross margin declined from 52.1% to 51.1% due to a shift in revenue mix toward lower-margin segments.

• Interim cash dividend of RMB0.0807 per share (tax inclusive) was proposed, totaling RMB25.81 million, subject to shareholder approval.

• Major breakthroughs included the launch of the first commercial carbon-14 isotope product and significant progress in radiopharmaceutical R&D and international market expansion.

• No material adverse changes or significant litigation were reported during the period.

Financial highlights

• Revenue: RMB2,857.8 million (up 1.7% YoY); net profit: RMB341.0 million (up 11.2% YoY); net profit attributable to shareholders: RMB172.0 million (up 11.3% YoY); EPS: RMB0.54 (up 12.5% YoY).

• Gross profit: RMB1,459.5 million (down 0.3% YoY); gross margin: 51.1% (down from 52.1%).

• Operating profit: RMB457.6 million (up 11.8% YoY); profit before tax: RMB431.1 million (up 9.9% YoY).

• Total assets: RMB15,651.8 million; net assets: RMB7,960.5 million as of 30 June 2025.

• Export revenue reached RMB349.5 million, up 63.4% YoY.

Outlook and guidance

• Focus on high-quality, stable growth, expanding investment, and accelerating international market development, especially in South America, Southeast Asia, the Middle East, and Belt and Road countries.

• Emphasis on scientific and technological innovation, with acceleration of clinical trials for 8 radiopharmaceuticals and new R&D projects.

• Strengthening production capacity, governance efficiency, and digital transformation initiatives.